Legal & General Group Plc Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Legal & General Group Plc lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 21.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 610,020 shares of the company's stock after selling 164,672 shares during the period. Legal & General Group Plc owned approximately 0.74% of IDEXX Laboratories worth $252,207,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after purchasing an additional 37,734 shares in the last quarter. Franklin Resources Inc. raised its position in IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after purchasing an additional 34,305 shares during the last quarter. Invesco Ltd. grew its holdings in IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after acquiring an additional 74,324 shares during the last quarter. Norges Bank acquired a new position in IDEXX Laboratories in the 4th quarter valued at approximately $412,258,000. Finally, American Century Companies Inc. lifted its holdings in shares of IDEXX Laboratories by 30.9% during the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company's stock worth $334,810,000 after purchasing an additional 191,385 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Up 2.3 %

Shares of NASDAQ:IDXX traded up $9.07 during trading on Monday, reaching $400.01. 175,356 shares of the stock were exchanged, compared to its average volume of 615,166. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The stock has a fifty day moving average of $428.03 and a two-hundred day moving average of $433.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market cap of $32.42 billion, a price-to-earnings ratio of 37.49, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

Analysts Set New Price Targets

A number of research firms have commented on IDXX. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.